A detailed history of Laurion Capital Management LP transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Laurion Capital Management LP holds 372,074 shares of SWTX stock, worth $14 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares
372,074
Previous 372,074 -0.0%
Holding current value
$14 Million
Previous $13.6 Million 34.85%
% of portfolio
0.16%
Previous 0.12%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$18.94 - $37.24 $132,390 - $260,307
-6,990 Reduced 1.84%
372,074 $13.6 Million
Q2 2023

Aug 14, 2023

SELL
$23.15 - $32.71 $431,330 - $609,452
-18,632 Reduced 4.68%
379,064 $9.94 Million
Q1 2023

May 15, 2023

BUY
$24.97 - $34.05 $25,719 - $35,071
1,030 Added 0.26%
397,696 $10.2 Million
Q3 2022

Nov 14, 2022

BUY
$24.1 - $39.66 $523,042 - $860,740
21,703 Added 5.79%
396,666 $11.3 Million
Q2 2022

Aug 15, 2022

BUY
$18.36 - $60.07 $3.81 Million - $12.5 Million
207,579 Added 124.01%
374,963 $9.23 Million
Q1 2022

May 16, 2022

SELL
$48.97 - $65.46 $875,436 - $1.17 Million
-17,877 Reduced 9.65%
167,384 $9.45 Million
Q3 2021

Nov 15, 2021

BUY
$62.66 - $88.26 $36,656 - $51,632
585 Added 0.32%
185,261 $11.8 Million
Q2 2021

Aug 13, 2021

SELL
$67.45 - $85.63 $2.27 Million - $2.88 Million
-33,590 Reduced 15.39%
184,676 $15.2 Million
Q1 2021

May 14, 2021

BUY
$65.1 - $93.59 $1.93 Million - $2.77 Million
29,586 Added 15.68%
218,266 $16.1 Million
Q4 2020

Feb 12, 2021

BUY
$48.36 - $77.92 $1.21 Million - $1.95 Million
25,000 Added 15.27%
188,680 $13.7 Million
Q4 2019

Feb 13, 2020

SELL
$17.74 - $39.52 $2.56 Million - $5.7 Million
-144,300 Reduced 46.85%
163,680 $6.3 Million
Q3 2019

Nov 13, 2019

BUY
$18.8 - $27.82 $5.79 Million - $8.57 Million
307,980 New
307,980 $6.68 Million

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2.35B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track Laurion Capital Management LP Portfolio

Follow Laurion Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Laurion Capital Management LP with notifications on news.